Glasdegib Recruiting Phase 2 Trials for Leukemia Acute Myeloid Leukemia (AML) / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04051996GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia